(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
07 May 2020 (07.05.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/092210 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)
A61K 45/06 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/US2019/058300

(22) International Filing Date:
28 October 2019 (28.10.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/752,904 30 October 2018 (30.10.2018) US

(71) Applicant: **GENMAB A/S** [DK/DK]; Kalvebod Brygge 43, 1560 Copenhagen V (DK).

(72) Inventor; and
(71) Applicant *(for BW only)*: **RANGWALA, Reshma Abdulla** [US/US]; c/o Genmab US, Inc., 902 Carnegie Center, Suite 301, Princeton, New Jersey 08540 (US).

(72) Inventors: **VERPLOEGEN, Sandra**; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). **BREIJ, Esther C.W.**; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). **ABIDOYE, Oyewale O.**; 11012 SE 64th Street, Bellevue, Washington 98006 (US). **NICACIO, Leonardo Viana**; 17409 NE 116th Way, Redmond, Washington 98052 (US).

(74) Agent: **BANKO, Max** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2020/092210 A1

(54) **Title:** METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-VEGF ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE

(57) **Abstract:** The invention provides an anti-VEGF antibody (*e.g.*, bevacizumab) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (*e.g.*, tisotumab vedotin) and their use in methods of treating cancer, such cervical cancer. The invention also provides compositions and kits comprising the anti-VEGF antibody (*e.g.*, bevacizumab) and the antibody-drug conjugate that binds to TF (*e.g.*, tisotumab vedotin) for use in treating cancer, such as cervical cancer.